Different therapy for different types of ulcerative colitis in China

Table 1 Therapeutic effects of Kangshuanling sublingual tablets on refractory UC patients

Group	Stool frequency (times/d)	Rectal bleeding (score)	Colonoscopy (score)	Histology (score)	Well-being (score)
Pre-treatment	8.2	2.7	2.6	12.0	3.9
Post-treatment	1.6b	0.3b	1.1b	5.0b	0.7b

^bP < 0.01 vs pretreatment.

Table 2 Effects of Kangshuanling sublingual tablet on CD62P and CD63, TXA2, platelet aggregation rate (PAR) and thrombosis length (TL) in vitro in UC patients (mean ± SD)

Group	CD62p (%)	CD63 (%)	TXA2 (ng/L)	PAR (%)	TL (cm)
UC patients
Pre-treatment	8.0 ± 3.1b	6.3 ± 2.1b	548.2 ± 84.9b	43.2 ± 10.1b	2.3 ± 0.6b
Post-treatment	4.1 ± 1.8a,d	3.2 ± 1.6a,d	390.1 ± 67.0d	34.8 ± 8.1d	1.8 ± 0.3d
Normal controls	1.9 ± 0.4	1.6 ± 0.8	340.2 ± 40.4	34.1 ± 9.1	1.7 ± 0.4

^aP < 0.05,

^bP < 0.01 vs normal controls;

^dP < 0.01 vs pretreatment.

Table 3 Effects of Kangshuanling sublingual tablets on CD54 in UC patients (mean ± SD, %)

Group	Blood CD54	Tissue CD54	Blood Pgp-170	Tissue Pgp-170
UC patients
Pre-treatment	26.9 ± 6.9b	51.1 ± 6.2b	18.9 ± 3.9b	16.5 ± 3.2b
Post-treatment	14.4 ± 5.1a,d	23.1 ± 4.1a,d	10.4 ± 2.7a,c	10.2 ± 2.3a,c
Normal controls	6.2 ± 3.7	8.8 ± 3.2	6.2 ± 2.2	6.8 ± 3.1

^aP < 0.05,

^bP < 0.01 vs normal controls;

^cP < 0.05 vs pre-treatment,

^dP < 0.01 vs pre-treatment.